My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

iShares Biotechnology ETF (NQ:IBB)

171.27 +2.77 (+1.64%)

Streaming Delayed Price Updated: 2:34 PM EDT, Apr 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about iShares Biotechnology ETF

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

28 29 Next >

Uncertainty Grips Markets-On A Clear Day Maybe You Can See A Week Ahead ↗

November 28, 2022

Healthcare stocks are now favored by many strategists because of their defensive nature and focus on US markets.

Via Talk Markets

Market Currents: Why Pick Stocks? ↗

November 28, 2022

Effective investing is changing. You can no longer just buy the S&P 500 and be done. Going forward you have to have a strategy and stock picking will become much more essential. Steve Brennan and...

Via Talk Markets

Look Who’s Leading Now ↗

November 01, 2022

All indexes are near either their 50 or 200 DMA’s as we head into the Fed’s announcement tomorrow.

Via Talk Markets

Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗

November 01, 2022

October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...

Via Benzinga

Can Biotech Stocks Continue Rallying In This Bear Market? ↗

October 31, 2022

Via Talk Markets

October Was Not So Scary After All - Things To Keep A Watch Out For ↗

October 31, 2022

Via Talk Markets

These 4 ETFs Feature on CNBC's 'Final Trades' ↗

October 27, 2022

On CNBC’s “Halftime Report Final Trades,” JPMorgan Private Bank’s Anastasia Amoroso chose iShares iBoxx $ High Yield Corporate Bond ETF (NYSE: HYG), saying that she wanted &ldq

Via Benzinga

Russell 2000: How Money Is Made And Lost In Small Caps ↗

October 19, 2022

IWM is in a bearish phase along with the other indices, but recent price action has shown relative strength.

Via Talk Markets

The Four Indices: Where Each Are In A 4-Year Cycle ↗

October 19, 2022

In the aftermath of last week’s market plunge and continued rally since, it is worth noting that the 200-week historic weekly support levels held for the SPY and the DIA, both of which were in danger...

Via Talk Markets

Steady As She Goes With Healthcare Stocks ↗

October 17, 2022

Favorable seasonality lies ahead for Q4 with a caveat of Q3 earnings reports.

Via Talk Markets

Precarious Action In The Bonds And Stock Market ↗

October 16, 2022

Analysts and researchers claimed that double thrusts in the market have always preceded positive returns. Always, huh?

Via Talk Markets

Taking The Temperature Of The Major Sector ETFs ↗

October 12, 2022

One of the most important first steps towards trading success is to tilt your trading towards trending sectors that display strength and avoid market weakness.

Via Talk Markets

3 Technical Lessons On Whether Or Not Semiconductors Bottomed ↗

October 03, 2022

The semis ETF SMH has three interesting technical features that are a reliable way to assess what to do from here and how to know if this rally will last.

Via Talk Markets

AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know ↗

October 02, 2022

Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...

Via Benzinga

The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market ↗

September 27, 2022

Despite the ongoing worries on Wall Street, these are the best stocks to buy to play the hidden bull market.

Via InvestorPlace

Step Back To The Monthly Chart On Transportation ↗

September 26, 2022

The chart of IYT is a perfect example of the monthly moving average and what to watch for.

Via Talk Markets

Can Healthcare Stocks Continue To Outperform? ↗

September 26, 2022

Large-cap healthcare and biotech stocks have been resilient amidst the market turmoil caused by rising rates and the global geopolitical crisis.

Via Talk Markets

The Biotech Sector Should Come Back First ↗

September 25, 2022

We are looking for profitable opportunities to deploy dry powder. Many areas of biotech show incredible promise, including regenerative medicine, gene therapy, genomics, new advances in treating cancer...

Via Talk Markets

The Major Sector ETFs Reveal All For Investors ↗

September 06, 2022

Semiconductors have been a significant drag on Wall Street.

Via Talk Markets

Healthcare Sector Still Looks Good But Lacks Momentum ↗

September 06, 2022

The summer rally is over it’s a holiday weekend with low trading volume and bad news is pervasive. A decent jobs report on Friday brought in buyers in early hours until Russia intervened with a Nord...

Via Talk Markets

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know ↗

August 31, 2022

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

Via Benzinga

Potential Signs That Could Derail The Economy ↗

August 21, 2022

The last six weeks have brought a partial market recovery. Most of the media and financial reporters have been telling us how much better everything now seems.

Via Talk Markets

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial ↗

August 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗

August 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases ↗

August 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗

August 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗

August 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study ↗

August 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial ↗

August 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Biotech Investors: August's Key PDUFA Catalysts You Must Know ↗

July 31, 2022

Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the...

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

28 29 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.